William J. Garner, M.D.
Martin E. Shmagin
Michael Goldberg, M.D., currently is a managing partner of Montaur Capital Partners, an investment firm, a position he has held since January 2007. From August 1990 to January 2007, Dr. Goldberg was Chairman and Chief Executive Officer of Emisphere Technologies. Prior to this, Dr. Goldberg was a Vice President for The First Boston Corporation, where he was a founding member of the Healthcare Banking Group. Dr. Goldberg has served as a Director of Adventrx Pharmaceuticals, Inc. (AMEX: ANX) since January 2004. He received a B.S. from Rensselaer Polytechnic Institute, an M.D. from Albany Medical College of Union University and an M.B.A. from Columbia University Graduate School of Business.
C. Lowell Parsons, M.D.,
Edward R. Teitel, M.D., J.D., M.B.A. currently serves as the President and Chief Executive Officer of ThromboVision, Inc. Prior to founding ThromboVision in 2005, Dr. Teitel served as Senior Vice President and Chief Medical Officer at MicroMed Technology, Inc. (now MicroMed Cardiovascular, Inc.). As a part of senior management at MicroMed, Dr. Teitel participated in all aspects of clinical trials and regulatory matters, business scope and fund raising activities, as well as legal matters. As chief medical officer for the DeBakey Left Ventricular Assist Device at MicroMed, Dr. Teitel acquired extensive experience in platelet function and anti-platelet therapy, especially relating to artificial surface devices. Before joining MicroMed Technology in 2002, Dr. Teitel practiced for many years as a board certified general and vascular surgeon. He founded, managed, and developed a multi-specialty group practice in Alabama until he closed his practice in 1997 to transition into corporate medicine and management. Dr. Teitel earned his MBA at Auburn University and worked with a boutique investment banking firm, Colby Capital, in Atlanta where he worked to fund start-up companies in the life sciences. After completing law school in 2002, he joined the senior management team at MicroMed. Dr. Teitel earned his MD degree at the University of Texas Health Science Center at San Antonio, and completed his surgical residency at St. Mercy Medical Hospital in Pontiac, Michigan. He received his Juris Doctor degree from the University of Houston, with a focus in healthcare law, intellectual property and business law. Dr. Teitel holds a BS in chemistry from Sul Ross State University.
Dan Vickery, Ph.D. is a pharmaceutical business development consultant. Prior to starting his practice in 2005, he held a senior business development position at Mylan Pharmaceuticals, overseeing their Branded Products and Drug Delivery divisions, during which he focused on transactions for Drug Delivery products in the EU, and in-licensing and out-licensing of branded products. Prior to joining Mylan, Dr. Vickery had worldwide commercial development responsibility at Pharmacia for the therapeutic areas of Urology, Women's Health Care, and Sexual Dysfunction. Dr. Vickery also has significant experience in drug development, having lead the Regulatory Affairs department at Parke-Davis division, Warner-Lambert Canada, during the time in which Lipitor was approved and launched. Dr. Vickery has an M.B.A. from the Ivey Business School, University of Western Ontario, and his Ph.D. (Genetics) and B.Sc. (Biology) are from the University of British Columbia.
Robert J. Watkins established R.J. Watkins & Company, Ltd., an executive recruiting and consulting firm, and currently serves as President and Chairman. Mr. Watkins' experience includes President and Chief Executive Officer of a $200 million entertainment company and Managing Director for the San Diego office of the international consulting firm of Russell Reynolds Associates. He has held executive positions with American Hospital Supply Corporation, serving on the corporation's acquisition and divestiture team. He also served as Management Consultant for the national accounting firm Deloitte & Touche. Mr. Watkins holds a BA degree from San Diego State University.
